PMID- 21312292
OWN - NLM
STAT- MEDLINE
DCOM- 20110825
LR  - 20181201
IS  - 1099-1077 (Electronic)
IS  - 0885-6222 (Linking)
VI  - 25
IP  - 7-8
DP  - 2010 Nov
TI  - Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a 
      randomized, placebo-controlled clinical trial.
PG  - 570-6
LID - 10.1002/hup.1158 [doi]
AB  - OBJECTIVE: The main aim of this study is to evaluate the efficacy of reboxetine, 
      a specific noradrenergic reuptake inhibitor, in adults with 
      attention-deficit/hyperactivity disorder (ADHD). METHODS: In a double blind 
      placebo-controlled clinical trial, the efficacy of 8 mg/day of reboxetine (twice 
      daily) was compared with placebo in 40 adults diagnosed with ADHD during 6 weeks. 
      The measures were Conners' Adult ADHD Rating Scale-Self-Report, Screening Version 
      (CAARS-S, SV), Hamilton Anxiety and Depression Rating Scales, Clinical Global 
      Impression - Severity Scale (CGI-S), and Global Assessment of Functioning Scale 
      (GAF). RESULTS: There was a main effect of time and significant time X treatment 
      (reboxetine vs. placebo) interaction on CAARS subscales and CGI scores which 
      decreased along the study (p < 0.01). There was also a main effect of time and 
      time X treatment interaction on GAF score which increased at the end point of the 
      study (p < 0.01). In terms of Hamilton Anxiety and Depression Rating Scales there 
      was just a main effect of time on Hamilton Depression Scale (p < 0.01). 
      Irritability, anxiety, sleep disturbance, and dry mouth were the common side 
      effects of reboxetine. CONCLUSION: Reboxetine could be used and tolerated as an 
      effective treatment for adults with ADHD.
CI  - Copyright (c) 2011 John Wiley & Sons, Ltd.
FAU - Riahi, Forough
AU  - Riahi F
AD  - Department of Psychiatry, Jondi Shapour University, Ahvaz, Iran.
FAU - Tehrani-Doost, Mehdi
AU  - Tehrani-Doost M
FAU - Shahrivar, Zahra
AU  - Shahrivar Z
FAU - Alaghband-Rad, Javad
AU  - Alaghband-Rad J
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Psychopharmacol
JT  - Human psychopharmacology
JID - 8702539
RN  - 0 (Antidepressive Agents)
RN  - 0 (Morpholines)
RN  - 0 (Placebos)
RN  - 947S0YZ36I (Reboxetine)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents/adverse effects/*therapeutic use
MH  - Attention Deficit Disorder with Hyperactivity/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Morpholines/adverse effects/*therapeutic use
MH  - Placebos
MH  - Psychiatric Status Rating Scales
MH  - Reboxetine
MH  - Treatment Outcome
EDAT- 2011/02/12 06:00
MHDA- 2011/08/27 06:00
CRDT- 2011/02/12 06:00
PHST- 2011/02/12 06:00 [entrez]
PHST- 2011/02/12 06:00 [pubmed]
PHST- 2011/08/27 06:00 [medline]
AID - 10.1002/hup.1158 [doi]
PST - ppublish
SO  - Hum Psychopharmacol. 2010 Nov;25(7-8):570-6. doi: 10.1002/hup.1158.